Across TCGA pan-cancer cohorts, FCER1G Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FCER1G data layer compared with 20 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FCER1G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FCER1G expression acts as an unfavorable survival marker.
HNSC, LUAD, and UCEC are the cancer types where FCER1G Mutation most reproducibly stratifies survival.